Telephos Intelligence solves high placebo response rates in CNS trials. This ""billion-dollar risk"" forces larger sample sizes (+100-200 patients) , inflating budgets by ~$8.4M. Total Phase III failure costs reach $800M-$1.4B per program. It also addresses low rater reliability; an ICC drop from 0.90 to 0.70 mandates a 22% sample size increase. 45% of development time adds no clinical value. Finally, it slashes inter-rater variability by 40-60%, enabling smaller, more precise, and cheaper trials.

Telephos Inteligence

Telephos Inteligence